DUBLIN–(BUSINESS WIRE)–The “Dyskinesia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Dyskinesia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 14, 8, 1, 27 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Dyskinesia – Overview
Dyskinesia – Therapeutics Development
Dyskinesia – Therapeutics Assessment
Dyskinesia – Companies Involved in Therapeutics Development
Dyskinesia – Drug Profiles
Dyskinesia – Dormant Projects
Dyskinesia – Discontinued Products
Dyskinesia – Product Development Milestones
- Adamas Pharmaceuticals Inc
- Addex Therapeutics Ltd
- AEON Biopharma Inc
- Amarantus Bioscience Holdings Inc
- Astraea Therapeutics LLC
- Bod Australia Ltd
- Cadent Therapeutics Inc
- Cannabis Science Inc
- Cavion LLC
- Cerevance Inc
- Cerevel Therapeutics LLC
- Contera Pharma ApS
- DanPET AB
- Domain Therapeutics SA
- EpiVax Inc
- GW Pharmaceuticals Plc
- H. Lundbeck AS
- Hua Medicine Shanghai Ltd
- Ipsen SA
- IRLAB Therapeutics AB
- Jazz Pharmaceuticals Plc
- Junaxo Inc
- Med-Life Discoveries LP
- Medytox Inc
- Melior Pharmaceuticals II LLC
- MitoDys Therapeutics Ltd
- Motac Neuroscience Ltd
- NeurAxon Pharma Inc
- Neurim Pharmaceuticals Ltd
- Neurocea Pharmaceuticals
- Neurocrine Biosciences Inc
- Neurolixis Inc
- Newron Pharmaceuticals SpA
- Nissan Chemical Corp
- OB Pharmaceuticals
- Peptron Inc
- PolyCore Therapeutics LLC
- Praxis Precision Medicines Inc
- Prilenia Therapeutics Development Ltd
- Revance Therapeutics Inc
- Sage Therapeutics Inc
- SalubRx Therapeutics Inc
- Sinopia Biosciences Inc
- SOM Biotech SL
- Sosei Heptares
- Teva Pharmaceutical Industries Ltd
- Trevi Therapeutics Inc
- Ultragenyx Pharmaceutical Inc
- VistaGen Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1e51f3